Alera Investment Advisors’s Novavax NVAX Stock Holding History

Alera Investment Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-250	Closed	-$9K	–	1285
2018 Q4	$9K	Buy	+250	New	+$9.69K	0.01%	464

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Alera Investment Advisors's NVAX Position: Q1 2019 in Review

Alera Investment Advisors sold out of Novavax (NVAX) in Q1 2019, closing a stake of 250 shares — an estimated $9K sold.

Alera Investment Advisors first reported a position in NVAX in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 140 funds tracked by Wall St. Rank hold NVAX as of Q1 2019.

Alera Investment Advisors reported no remaining Novavax position as of Q1 2019 after selling out during the quarter.
Alera Investment Advisors sold 250 Novavax shares in Q1 2019, an estimated $9K.
Alera Investment Advisors first reported a position in Novavax in Q4 2018 and held it in 1 quarter.
Alera Investment Advisors's Novavax position peaked at $9K in Q4 2018.
140 funds tracked by Wall St. Rank held Novavax as of Q1 2019.

Based on Alera Investment Advisors's 13F filing for Q1 2019, filed 14 May 2019.